Trexquant Investment’s Structure Therapeutics GPCR Stock Holding History

Trexquant Investment’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-107,884	Closed	-$5.2M	–	2023
2026 Q1	$5.2M	Buy	107,884 +17,939	+20%	+$1.23M	0.04%	634
2025 Q4	$6.26M	Buy	89,945 +69,753	+345%	+$2.85M	0.06%	491
2025 Q3	$565K	Sell	20,192 -61,396	-75%	-$1.22M	0.01%	1295
2025 Q2	$1.69M	Sell	81,588 -38,752	-32%	-$852K	0.02%	938
2025 Q1	$2.08M	Buy	120,340 +67,464	+128%	+$1.65M	0.02%	858
2024 Q4	$1.43M	Buy	52,876 +45,235	+592%	+$1.6M	0.02%	979
2024 Q3	$335K	Sell	7,641 -55,829	-88%	-$2.16M	﹤0.01%	1326
2024 Q2	$2.49M	Buy	63,470 +33,529	+112%	+$1.38M	0.04%	661
2024 Q1	$1.28M	Buy	+29,941	New	+$1.26M	0.03%	828

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Trexquant Investment's GPCR Position: Q2 2026 in Review

Trexquant Investment sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 107,884 shares — an estimated $5.2M sold.

Trexquant Investment first reported a position in GPCR in Q1 2024 and held it in 9 quarters. The position peaked at $6.26M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Trexquant Investment reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
Trexquant Investment sold 107,884 Structure Therapeutics shares in Q2 2026, an estimated $5.2M.
Trexquant Investment first reported a position in Structure Therapeutics in Q1 2024 and held it in 9 quarters.
Trexquant Investment's Structure Therapeutics position peaked at $6.26M in Q4 2025.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.